Compass Capital Corp MA ADV Invests $188,000 in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Compass Capital Corp MA ADV acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 800 shares of the biopharmaceutical company’s stock, valued at approximately $188,000.

Several other institutional investors also recently bought and sold shares of the business. Creative Planning increased its holdings in shares of Alnylam Pharmaceuticals by 24.6% in the 3rd quarter. Creative Planning now owns 10,012 shares of the biopharmaceutical company’s stock valued at $2,754,000 after acquiring an additional 1,978 shares during the period. Blue Trust Inc. boosted its position in Alnylam Pharmaceuticals by 431.0% during the third quarter. Blue Trust Inc. now owns 462 shares of the biopharmaceutical company’s stock valued at $127,000 after purchasing an additional 375 shares in the last quarter. Allspring Global Investments Holdings LLC grew its stake in Alnylam Pharmaceuticals by 62.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 420 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 161 shares during the last quarter. Signaturefd LLC raised its holdings in Alnylam Pharmaceuticals by 34.1% in the third quarter. Signaturefd LLC now owns 1,854 shares of the biopharmaceutical company’s stock worth $510,000 after purchasing an additional 471 shares in the last quarter. Finally, Lecap Asset Management Ltd. purchased a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at about $669,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research analysts have recently issued reports on the stock. StockNews.com downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Raymond James lifted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. Piper Sandler reiterated an “overweight” rating and set a $296.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. Needham & Company LLC restated a “buy” rating and set a $320.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, February 14th. Finally, Morgan Stanley increased their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $299.48.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Tolga Tanguler sold 1,469 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $368,689.62. Following the sale, the executive vice president now directly owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This trade represents a 10.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the transaction, the executive vice president now directly owns 14,321 shares of the company’s stock, valued at approximately $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,356 shares of company stock valued at $22,498,551. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Stock Down 0.2 %

Alnylam Pharmaceuticals stock opened at $250.59 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The firm has a market cap of $32.44 billion, a price-to-earnings ratio of -115.48 and a beta of 0.35. The business’s 50-day moving average price is $254.14 and its 200 day moving average price is $263.02. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.